Immunogenicity of Sequences Around HIV-1 Protease Cleavage Sites: Potential Targets and Population Coverage Analysis for a HIV Vaccine Targeting Protease Cleavage Sites
Overview
Authors
Affiliations
Developing an effective preventative vaccine against HIV-1 has proved to be a great challenge. The classical and proven vaccine approach has failed so far or produced a modest effect, new approaches are needed. In this study we evaluated the immunogenicity of the sequences around the protease cleavage sites (PCS) and the population coverage of a vaccine targeting HIV-1 PCS. The sequence conservation was evaluated by comparing entropy score of sequences around PCS with Gag and Pol. The immunogenicity of sequences around the 12 PCS (+10/-10 amino acids) was analyzed by identifying epitopes of HLA class I alleles in PCS region using four approaches: (1) identification of previously reported HLA class I allele epitopes around PCS region; (2) screening and validating epitopes of 8 HLA class I alleles common to most world populations using iTopia Epitope Discovery system and IFN-γ ELISpot assays; (3) screening of 151 patients of Pumwani cohort for PBMC IFN-γ ELISPOT responses to the subtype A and D consensus around PCS region; and (4) prediction of HLA alleles with epitopes around the PCS using NetMHCpan. Population coverage was calculated using the web-based analysis tool of the Immune Epitope Database based on HLA class I genotype frequencies from dbMHC database. The results showed that many HLA class I alleles have multiple epitopes in the 12 PCS regions, indicating sequence immunogenicity around PCS. Multiple epitopes of many HLA class I alleles common to >95% world populations have been identified around the 12 PCS region. Targeting these sites is a feasible vaccine approach.
Mandal S, Ghosh J, Lohani S, Zhao M, Cheng Y, Burrack R Emerg Microbes Infect. 2024; 13(1):2377606.
PMID: 38979723 PMC: 11259082. DOI: 10.1080/22221751.2024.2377606.
Natural Immunity against HIV-1: Progression of Understanding after Association Studies.
Luo M Viruses. 2022; 14(6).
PMID: 35746714 PMC: 9227919. DOI: 10.3390/v14061243.
Polymeric nanoparticle vaccines to combat emerging and pandemic threats.
Wibowo D, Jorritsma S, Gonzaga Z, Evert B, Chen S, Rehm B Biomaterials. 2020; 268:120597.
PMID: 33360074 PMC: 7834201. DOI: 10.1016/j.biomaterials.2020.120597.
Vaccine targeting SIVmac251 protease cleavage sites protects macaques against vaginal infection.
Li H, Omange R, Liang B, Toledo N, Hai Y, Liu L J Clin Invest. 2020; 130(12):6429-6442.
PMID: 32853182 PMC: 7685735. DOI: 10.1172/JCI138728.
Dacoba T, Omange R, Li H, Crecente-Campo J, Luo M, Alonso M ACS Nano. 2019; 13(5):4947-4959.
PMID: 30964270 PMC: 6607401. DOI: 10.1021/acsnano.8b07662.